Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy.

UTMD Anderson Cancer Center, Houston, Texas, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, Texas
Treatments:ChemotherapyHospital:UTMD Anderson Cancer Center
Drugs:Journal:Link
Date:Sep 2000

Description:

Patients: This Phase II study involved 225 glioblastoma multiforme patients at first relapse who were divided into two groups of 112 patients and 113 patients.

Treatment: The group of 112 patients were administered the chemotherapy drug temozolomide (temodar). The group of 113 patients were administered the chemotherapy drug procarbazine (matulane).

Toxicity: For both groups, grade 3-4 toxicities included: nausea, vomiting, fatigue, constipation, headache, thrombocytopenia, neutropenia, and anemia.

Results: For the procarbazine group of patients, the 6-month progression free survival rate was 8%. Overall median survival was not detailed.





Back